Evidence map›Paper›PMID 42386746›Full record

ArticleNature communications2026

Targeting rapidly cycling receptors CD2 and CD7 increases nanoparticle delivery to primary CD4

Paula M Cevaal, Abdalla Ali, Marcel Doerflinger, Christina Cortez-Jugo, Abigail Tan, Haiyin Liu, Moore Z Chen, Le Wang, Merle Dayton, Liana Mackiewicz and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Paula M CevaalDepartment of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0003-4473-7904
Abdalla AliDepartment of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-6946-4343
Marcel DoerflingerThe Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0001-9159-3021
Christina Cortez-JugoDepartment of Chemical Engineering, The University of Melbourne, Parkville, VIC, Australia.
Abigail TanDepartment of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Haiyin LiuMonash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia.
Moore Z ChenMonash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia.ORCID http://orcid.org/0000-0002-4234-5117
Le WangThe Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Merle DaytonThe Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Liana MackiewiczThe Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-4340-4975
Stanislav KanDepartment of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Matthew FariaDepartment of Biomedical Engineering, The University of Melbourne, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0003-1729-5813
Celine GubserDepartment of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
René P M LafleurDepartment of Chemical Engineering, The University of Melbourne, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0003-0026-3428
Robert De RoseDepartment of Chemical Engineering, The University of Melbourne, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0003-4316-3910
Angus P R JohnstonMonash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia.ORCID http://orcid.org/0000-0001-5611-4515
Frank CarusoDepartment of Chemical Engineering, The University of Melbourne, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0002-0197-497X
Michael RocheDepartment of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Jori SymonsDepartment of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0001-6560-1577
Sharon R LewinDepartment of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia. sharon.lewin@unimelb.edu.au.ORCID http://orcid.org/0000-0002-0330-8241

Funding

Delaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0M
amfAR, The Foundation for AIDS Research (amfAR) 110406-73-RGRLDepartment of Health | National Health and Medical Research Council (NHMRC) 1135851Department of Health | National Health and Medical Research Council (NHMRC) 2016732Department of Health | National Health and Medical Research Council (NHMRC) 2026490Department of Health | National Health and Medical Research Council (NHMRC) GNT1149990,Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) UM1AI164560NIAID NIH HHS UM1 AI164560
6 · The paper itself

Abstract

T cells are critically important to many diseases but are traditionally difficult to transfect. We hypothesise that the delivery of therapeutic cargo to T cells can be improved by targeting nanoparticles to surface receptors that undergo rapid receptor-mediated endocytosis. Using an internalisation assay that labelled intracellular and surface proteins with different fluorophores, we find that CD2 and CD7 exhibit significantly higher internalisation than other T cell receptors, such as CD3 or CD4. Targeting CD2 and CD7 improves nanoparticle internalisation by non-stimulated, primary CD4

Indexed as

Antigens, CD7CD2 AntigensCD4-Positive T-LymphocytesNanoparticlesAnimalsDrug Delivery SystemsEndocytosisHumansMiceMice, Inbred C57BLRNA, MessengerAntigens, CD7CD2 AntigensRNA, Messenger

Identifiers

PMID42386746
PMCPMC13462104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.